Title of Invention | TRICYCLIC THROMBIN RECEPTOR ANTAGONISTS OF FORMULA I |
---|---|
Abstract | Heterocyclic-substituted tricyclics of the formula or a pharmaceutically acceptable salt thereof,; wherein. the dotted line represents an optional single bond; represents an optional double bond; n is 0-2; Rio Q is R-substituted cycloalkyl, optionally additionally substituted by R13 and R is –NHCOOR16b, -NHCOR16b,-NHCONR4R5or-NHSO2R16 Het is a mono- or bicyclic optionally substituted and heteroaromatic group; 8 is a bond, alkylene, or optionally substituted alkenylene or alkynylene, wherein the remaining substituents are as defined in the specification, are disclosed, as well as pharmaceutical compositions containing them and a method of treating diseases associated with thrombosis, atherosclerosis, restenosis, hypertension, angina pectoris, arrhythmia, heart failure, and cancer by administering said compounds. Combination therapy with other cardiovascular agents is also claimed. |
Full Text |
---|
2291-chenp-2004 correspondence others.pdf
2291-chenp-2004 correspondence others.pdf
2291-chenp-2004 correspondence po.pdf
2291-chenp-2004 description (complete).pdf
Patent Number | 218783 | ||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Indian Patent Application Number | 2291/CHENP/2004 | ||||||||||||||||||||||||
PG Journal Number | 21/2008 | ||||||||||||||||||||||||
Publication Date | 23-May-2008 | ||||||||||||||||||||||||
Grant Date | 16-Apr-2008 | ||||||||||||||||||||||||
Date of Filing | 11-Oct-2004 | ||||||||||||||||||||||||
Name of Patentee | SCHERING CORPORATION | ||||||||||||||||||||||||
Applicant Address | 2000 Galloping Hill Road, Kenilworth, New Jersey 07033 - 0530, | ||||||||||||||||||||||||
Inventors:
|
|||||||||||||||||||||||||
PCT International Classification Number | C07D 05/06 | ||||||||||||||||||||||||
PCT International Application Number | PCT/US2003/011510 | ||||||||||||||||||||||||
PCT International Filing date | 2003-04-14 | ||||||||||||||||||||||||
PCT Conventions:
|